Psychedelic Access in Europe: What Changed – October 2026

Regulatory access to psychedelic and ketamine-family treatment in Europe changes in small, dated steps (a billing decision here, a trial approval there), that rarely make headlines but determine what patients can actually get. This page is a monthly monitor of those steps: what changed in the last ~30 days, country by country, each item with a date and a primary source. It is a companion to our standing reference pages: is ketamine therapy legal in Europe?, where in Europe you can get psychedelic therapy and the statistics page, which describe the stable picture; this one records the movement.

This issue: October 2026 (issue 2), covering roughly 3 September – 2 October 2026. Last verified: 2 October 2026.

The global context item

• MDMA NDA resubmitted in the US (filing 8-9 August, publicly reported mid-September). Resilient Pharmaceuticals, the successor to MAPS PBC/Lykos Therapeutics, resubmitted the New Drug Application for MDMA-assisted therapy for PTSD to the US FDA, explicitly without conducting the new Phase 3 trial the FDA's 2024 Complete Response Letter had requested, citing instead the FDA's July 2026 guidance on psychedelic drug development. Why it appears in a European tracker: a US approval would not change any European authorisation, but it historically moves sponsor priorities, trial siting and investor attention in Europe, and the EU decides separately (the latest published EMA list of medicines under evaluation still does not include midomafetamine). Sources: Psychedelic Alpha, the refile report; MAPS statement.

Norway

• 3 July 2026 (caught up from the previous window): manualized MDMA pilot approved. CTIS shows a Norwegian decision for a randomized, delayed-treatment controlled Phase 2 pilot study of manualized MDMA-assisted therapy (CT no. 2024-520319-42-01). Together with the 2024-approved KeDA ketamine trial in Tromsoe, it extends the Nordic research map. We missed this decision in issue 1 and record it here with its original date. Source: EU Clinical Trials Register (CTIS), CT 2024-520319-42-01.
• Context, unchanged: Norway's payer rejected Spravato but funds generic IV ketamine for treatment-resistant depression at hospital clinics; the NORAAD network continues. See the Norway block on the access page.

Latvia

• Status, not new this window but newly in our records: the National Mental Health Centre (NPVC) in Riga runs state-funded esketamine therapy for treatment-resistant depression, access by medical-council (konsilijs) decision; the centre reported 29 patients treated under state funding as of August 2025. We add it here because small-market programmes like this rarely get reported anywhere. Source: NPVC announcement.

Czechia

• Status, October 2026: unchanged. The psilocybin framework (in force since 1 January 2026) remains in rollout; the national clinical guideline is published and early providers still publicly expect first treatments in the second half of 2026. We will record the first confirmed treatment as a dated item when it happens. Sources as in issue 1 (archived below).

Germany

• Status, October 2026: unchanged. The 13 August decision keeping esketamine post-dose observation billing (GOP 01549) restricted to psychiatric specialties stands; we found no new Bewertungsausschuss activity in this window. Context and sources in the archive below and in the Germany access guide.

United Kingdom

• Status, October 2026: unchanged. Psilocybin remains Schedule 1; the licence-exemption pilot for universities and NHS trial sites remains in design. Sources in the archive below.

What did not happen, on the record

Our CTIS monitor (refreshed 1 October against the live register) shows no new psychedelic or ketamine-family trial approvals with European decision dates inside this window. Quiet months are information too: the access picture a patient faces in October is the same one described in our country guides, and the newest movement remains the trial approvals and billing decisions listed in the archive below.

Archive: September 2026 (issue 1)

Germany

• 13 August 2026: Esketamine observation billing stays restricted to psychiatric specialties. The KBV (National Association of Statutory Health Insurance Physicians) proposed, in the Bewertungsausschuss, extending the right to bill for the mandatory post-dose observation of intranasal esketamine (Spravato) (currently billing code GOP 01549, introduced October 2023) to GPs, neurologists and other specialist groups, so patients could be monitored closer to home. The insurer side rejected the draft outright; the KBV board publicly criticised the decision as "a lost chance to improve care for these severely ill patients". Practical effect: supervised esketamine administration in Germany remains billable only in a narrow set of psychiatric specialties, which is a real capacity ceiling given the multiple-sessions-per-week induction schedule. Source: KBV press release, 13.08.2026; background on the code: KV Hessen — Spravato observation billing.
• Context, unchanged: esketamine remains reimbursed with a G-BA "considerable added benefit" rating since 2023; Germany's two-site psilocybin compassionate-use programme continues. See the Germany access guide.

Netherlands

• 26 August 2026: MDMA trial approved. CTIS records show a national decision for a Phase II (therapeutic exploratory) trial of MDMA for post-traumatic stress disorder, sponsored by Stichting Amsterdam UMC (CT no. 2024-515184-65-01), with two Dutch sites. For a country whose state commission urged movement on therapeutic MDMA while the cabinet kept to the regular medicines route, investigator-led trials are currently where that movement happens. Source: EU Clinical Trials Register (CTIS), CT 2024-515184-65-01.
• Context, unchanged: psilocybin and MDMA remain clinical-research-only in Dutch healthcare; esketamine is reimbursed from the basic package under treatment-resistant depression conditions. See the Netherlands access guide.

Denmark

• 1 August 2026: Psilocybin for anorexia nervosa approved. CTIS shows a Danish decision for a Phase II psilocybin trial in anorexia nervosa, sponsored by Slagelse Hospital (CT no. 2025-524939-39-02): a notable indication choice, since anorexia is among the deadliest psychiatric conditions and has no approved pharmacotherapy. Source: EU Clinical Trials Register (CTIS), CT 2025-524939-39-02.
• Context, unchanged: Denmark's route to psychedelic treatment remains research participation; ketamine/esketamine follow the hospital system. See the Denmark access guide.

Italy

• 14 August 2026: Psilocybin + trazodone dose-finding study approved. CTIS shows an Italian decision for a Phase IIa open-label study evaluating whether trazodone can attenuate the consciousness-altering effects of psilocybin in treatment-resistant depression, sponsored by the University of Chieti (CT no. 2025-523346-27-00), four Italian sites. If the attenuation concept holds, it speaks to a live scientific question: whether the subjective experience is required for the antidepressant effect. Source: EU Clinical Trials Register (CTIS), CT 2025-523346-27-00.

Czechia

• Status, September 2026: the EU's first psilocybin framework is live but not yet treating. The Czech framework permitting psilocybin-assisted treatment in healthcare facilities (the first of its kind in the EU) has been in force since 1 January 2026, limited to defined severe-depression indications under certified psychiatric teams. The Czech Psychiatric Society's 2026 recommended-practice guideline for psilocybin treatment is published, and early providers publicly expect first treatments in the second half of 2026, with initial capacity of a few dozen patients a year, mainly Prague and Brno. Sources: Czech Psychiatric Society, Doporučené postupy 2026 — psilocybin treatment; Zdravotnický deník interview on the 2026 rollout.

United Kingdom

• Status, September 2026: pilot still in design, no rescheduling. No new public decision fell in this window. The standing position: on 16 July 2025 the government formally accepted, in principle, the ACMD's recommendation to let universities and NHS clinical-trial sites conduct Schedule 1 research (including psilocybin) without a separate controlled-drugs licence, to be tested through a pilot scheme; a written parliamentary answer of 27 October 2025 confirmed the pilot was being designed. Psilocybin itself remains Class A, Schedule 1, and there is no UK medical psilocybin access route. Sources: UK Parliament written answer 85461, 27.10.2025; Parliamentary POST briefing on psychedelic-assisted therapy policy.

Switzerland

• Status, September 2026: the limited-medical-use programme continues; no fresh decision this window. The most recent published programme data remain those of the 2025 BAG-commissioned evaluation: roughly 700 FOPH exceptional-use permits in 2024 (LSD, MDMA and psilocybin under Article 8(5) NarcA) and around 100 authorised treating physicians. We found no newer official figures in this window; when BAG publishes 2025/2026 numbers, they will appear here. Sources: BAG — limited medical use of prohibited narcotics; Meier et al. 2025 — history and characteristics of the Swiss limited medical use programme.

Austria

• Nothing verified this window. We found no dated regulatory or access change in psychedelic or ketamine-family medicine in Austria between early July and early September 2026 that we could trace to a primary source. An empty section is information too: no movement, and a record of that fact.

What we deliberately leave out

This tracker covers psychedelic and ketamine-family medicine only. Cannabis regulation (including Spain's Royal Decree 903/2025 on medical cannabis) moves on its own track and is out of scope here, even where the same agencies (SÚKL, BAG) administer both. Trials data comes from the EU's CTIS register via our scheduled refresh plus a manual check at publication; the full picture of what is recruiting right now lives in our live index of recruiting trials, re-verified on this monitor's monthly cycle, and how to read trial phases and what participation involves is in our clinical trials guide.

How this tracker works

New issue monthly; this September 2026 edition is issue 1. Each item carries the decision date, what changed in practical terms, and a primary source: regulator, register or official press release, never news aggregation alone. Items from previous windows move to an archive section as issues accumulate. If you spot a dated, sourceable change we missed, write to hello@psyaccess.health.

How to cite this page

Cite as: PsyAccess, "Psychedelic Access in Europe: What Changed – September 2026", psyaccess.health, last verified 3 September 2026, https://psyaccess.health/guides/psychedelic-access-updates/. Each dated item carries its primary source above; you are welcome to reuse individual items with attribution.

This page tracks regulation and availability; it is not medical advice, and inclusion of a treatment or trial is not a recommendation. For whether any route is open to you, start with the eligibility check or your clinician.